Evidence map›Paper›PMID 35942110›Full record

ArticleGynecologic oncology reports2022

Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events.

Karen A Monuszko, Laura J Fish, Dorinda Sparacio, Christina Lizaso, Kathryn Burn, Natalie E Wickenheisser, Larissa A Meyer, Shelby D Reed, Brittany A Davidson, Laura J Havrilesky

Open access · goldAbstract read
In one paragraph

Article in Gynecologic oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Karen A MonuszkoDuke University School of Medicine, Durham, NC 27710, USA.
Laura J FishDepartment of Family Medicine and Community Health, Duke University School of Medicine, Durham, NC 27710, USA.
Dorinda Sparacio#gyncsm (Gynecologic Cancer Social Media) Community, USA.
Christina Lizaso#gyncsm (Gynecologic Cancer Social Media) Community, USA.
Kathryn BurnSmart Patients Online Community, USA.
Natalie E WickenheisserDuke University School of Medicine, Durham, NC 27710, USA.
Larissa A MeyerGynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shelby D ReedDuke Clinical Research Institute, Durham, NC 27710, USA.
Brittany A DavidsonDivision of Gynecologic Oncology, Duke Cancer Institute, Durham, NC 27710, USA.
Laura J HavrileskyDivision of Gynecologic Oncology, Duke Cancer Institute, Durham, NC 27710, USA.
Duke University · USDuke Cancer InstituteDuke Medical Center · USPatients First · USThe University of Texas MD Anderson Cancer Center · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
NCI NIH HHS P30 CA014236
6 · The paper itself

Abstract

Objective: The online environment is an ideal setting to understand how many women seek, receive, and understand information about cancer treatment. The purpose of this study was to understand women's needs and information-seeking around Poly ADP ribose polymerase (PARP) inhibitors, an oral medication commonly prescribed as maintenance therapy at the conclusion of primary chemotherapy for ovarian cancer. Methods: We held online discussion events with two social media communities, #gyncsm social media on Twitter and the Smart Patients ovarian cancer community, in November 2020, to sample ovarian cancer patient perceptions of, and information seeking about PARP inhibitors. Focused questions were presented to both communities, with participants able to answer and elaborate upon these questions, as well as to add their own comments or topics. Qualitative content analysis was performed on the transcripts from the two online events. Results: A total of 254 unique tweets and 71 messages were generated from the Twitter and Smart Patients conversations, respectively. The majority of the content from these two events could be categorized into five major themes: (1) concerns about side effects, (2) expectations of benefit, (3) desire for more information regarding clinical trials, ) (4) desire to better understand the relationship between mutation status and PARP inhibitor effectiveness, and (5) financial toxicity. Misinformation was rarely identified. Conclusions: Women with ovarian cancer who are engaged in online patient communities have numerous educational needs regarding PARP inhibitors. Given the complexity of clinical research on PARP inhibitors, patients would likely benefit from patient-centered educational tools.

Indexed as

Ovarian cancerPARP-inhibitorsPatient educationSocial media

Identifiers

PMID35942110
PMCPMC9356188
OpenAlexW4288046064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.